SynuClean-D

Research use only, not for human use.

SynuClean-D is an α-synuclein aggregation inhibitor preventing fibril propagation, disrupting mature amyloid fibrils, and abolishing the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease.

SynuClean-D is an α-synuclein aggregation inhibitor preventing fibril propagation, disrupting mature amyloid fibrils, and abolishing the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease.(In Vitro):SynuClean-D prevents fibril propagation in protein-misfolding cyclic amplification assays and decreases the number of α-synuclein inclusions in human neuroglioma cells. SynuClean-D significantly reduces the aggregation of wild-type α-synuclein and the familiar A30P and H50Q variants in a substoichiometric molar ratio. SynuClean-D can bind to cavities in mature α-synuclein fibrils.(In Vivo):SynuClean-D-treated worms show decreased α-synuclein aggregation in muscle and a concomitant motility recovery. SynuClean-D is able to rescue dopaminergic neurons from α-synuclein-induced degeneration. In two parkinson’s disease (PD) Caenorhabditis elegans models, SynuClean-D expresses α-synuclein either in muscle or in dopaminergic neurons and significantly reduces the toxicity exerted by α-synuclein.

SynuClean-D significantly reduces the in vitro aggregation of wild-type α-synuclein and the familiar A30P and H50Q variants in a substoichiometric molar ratio. SynuClean-D prevents fibril propagation in protein-misfolding cyclic amplification assays and decreases the number of α-synuclein inclusions in human neuroglioma cells. Computational analysis suggests that SynuClean-D can bind to cavities in mature α-synuclein fibrils and, indeed, it displays a strong fibril disaggregation activity.

The treatment with SynuClean-D of two parkinson’s disease (PD) Caenorhabditis elegans models, expressing α-synuclein either in muscle or in dopaminergic neurons, significantly reduces the toxicity exerted by α-synuclein. SynuClean-D-treated worms show decreased α-synuclein aggregation in muscle and a concomitant motility recovery. More importantly, this compound is able to rescue dopaminergic neurons from α-synuclein-induced degeneration.

SC-D

Others

Other Targets

PRPP Amidotransferase

——

——

685121-45-3

354.201

C13H5F3N4O5

>98% (HPLC)

In Vitro:?DMSO : 83.33 mg/mL (235.26 mM)

Oc1nc(-c2cccc(c2)[N+]([O-])=O)c(c(c1C#N)C(F)(F)F)[N+]([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years